Bcl-2-like 1 | B-cell lymphoma 2 (Bcl-2) protein family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

Bcl-2-like 1

  Target has curated data in GtoImmuPdb

Target id: 2845

Nomenclature: Bcl-2-like 1

Abbreviated Name: Bcl-xL

Family: B-cell lymphoma 2 (Bcl-2) protein family

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 233 20q11.21 BCL2L1 BCL2 like 1
Mouse - 233 2 H1 Bcl2l1 BCL2-like 1
Rat - 233 3q41.2 Bcl2l1 Bcl2-like 1
Gene and Protein Information Comments
A shorter human isoform, Bcl-xS, is produced from transcript variant NM_001191 (170 aa). A longer mouse isoform Bcl-x gamma, is produced from transcript variant NM_001289739 (235 aa). For the rat gene we represent the isoform analoghous to the human and mouse in the table above. Note that both a longer rat isoform (284 aa) and a shorter isoform (170 aa) have been reported.
Previous and Unofficial Names
Bcl-X | BCLX | BCL2-like 1
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of Bcl-xL in complex with ABT-737.
Ligand:  ABT-737
Resolution:  2.2Å
Species:  Human
References:  2

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
ABT-737 Hs Antagonist >9.3 pKi 1
pKi >9.3 (Ki <5x10-10 M) [1]
navitoclax Hs Antagonist >9.0 pKi 3
pKi >9.0 (Ki <1x10-9 M) [3]
venetoclax Hs Antagonist 7.3 pKi 4
pKi 7.3 (Ki 4.8x10-8 M) [4]
Immunopharmacology Comments
The role of Bcl-2 family members in immunity and disease is reviewed in [5]. Pharmacological inhibition of Bcl-2 family proteins reduces disease severity in several animal models of autoimmunity; see ligand ABT-737 [1].
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 6 GO processes
GO:0019221 cytokine-mediated signaling pathway TAS
GO:0034097 response to cytokine IDA
GO:0036017 response to erythropoietin IEP
GO:0036018 cellular response to erythropoietin IEP
GO:0071347 cellular response to interleukin-1 IEP
GO:0071356 cellular response to tumor necrosis factor IEP
Immuno Process:  Antigen presentation
GO Annotations:  Associated to 2 GO processes, IEA only
GO:1900244 positive regulation of synaptic vesicle endocytosis ISO
click arrow to show/hide IEA associations
GO:0006897 endocytosis IEA


Show »

1. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC et al.. (2007) Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem., 50 (4): 641-62. [PMID:17256834]

2. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ., 14 (9): 1711-3. [PMID:17572662]

3. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, Marsh KC, Nimmer P, Shoemaker AR, Song X et al.. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem., 51 (21): 6902-15. [PMID:18841882]

4. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al.. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med., 19 (2): 202-8. [PMID:23291630]

How to cite this page

B-cell lymphoma 2 (Bcl-2) protein family: Bcl-2-like 1. Last modified on 18/12/2017. Accessed on 20/09/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2845.